Aster DM Healthcare delivered a strong performance in Q3FY25, supported by revenue growth and operational efficiencies.

The company clarified that, since GCC operations are now a segregated entity, the ₹179.2 crore net profit reported in Q3FY24 included ₹116.2 crore from discontinued operations.

Therefore, the correct comparison is based on the adjusted net profit (post NCI) for the India business, which grew 30% YoY to ₹81 crore in Q3FY25, up from ₹62 crore in Q3FY24.

For the quarter, revenue grew 11% YoY to ₹1,050 crore, while operating EBITDA increased 20% YoY to ₹202 crore, with margins expanding to 19.3% from 17.7% YoY.

For the nine-month period (9M FY25), the company reported an 65% YoY increase in adjusted net profit (post NCI) to ₹251 crore.

The company’s PBT surged 103% YoY to ₹413 crore in 9M FY25, reflecting strong core business performance.

Also read: Sun Pharma Q3 beats estimates, net profit rises 19%; declares ₹10.50 interim dividend

Aster DM also provided an update on its merger with Quality Care India Limited, stating that shareholder approvals have been secured, with regulatory clearances pending. The transaction is expected to close after obtaining approvals from the CCI, stock exchanges, and NCLT.

For 9M FY25, revenue grew 15% YoY to ₹3,138 crore, while operating EBITDA surged 35% YoY to ₹613 crore, with margins improving to 19.5% from 16.6% YoY.

The board of directors also approved an interim dividend of ₹4 per equity share.

The company continues to expand its capacity, with plans to add ~1,700 beds by FY27, strengthening its position in India’s healthcare market.